We are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases (cancer, neuromuscular disease and infectious diseases) with high unmet medical need. Exosomes are intercellular transfer mechanisms; they have emerged in recent years as […]

We are a biopharmaceutical company using our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Our primary focus is oncology (cancer) but our technology may also have applications in the discovery of new therapeutics for infectious diseases, including COVID-19. Our […]

We intend to focus on opportunities in the technology sector, particularly companies pursuing a Software as a Service, or SaaS, model. Software companies will continue to benefit in the shift of more companies toward a remote workforce or a more distributed workforce, which is happening due in large part to the COVID-19 pandemic. With a $300 […]

We intend to focus our search for prospects within the insurance industry, including insurance tech (InsurTech) companies and  traditional insurance or insurance services companies.

  We are a clinical-stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Using our two distinct proprietary platforms, we are developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors.  […]

We intend to focus our search for a suitable initial business combination target in the next-generation mobility, transportation and sustainable industrial technology sectors, but we may pursue an initial business combination target in any stage of its corporate evolution or in any industry, sector or geographic location. Barry Engle, our chief executive officer, and Sam […]

(Note: GRAIL, Inc., withdrew its IPO plans on Aug. 23, 2021, following completion of its acquisition on Aug. 18, 2021, by Illumina. The U.S. Federal Trade Commission is challenging the acquisition and the matter is set to go to trial today – Aug. 24, 2021, at the FTC. This case marks the first “vertical” trial […]

This is a new blank check company led by Brenton L. Saunders, the former CEO of Allergan plc, best known for Botox, its wrinkle erasing product. From the prospectus: “We intend to focus on the pharmaceuticals and healthcare sectors with an emphasis on companies in the medical aesthetics, eye care, longevity and wellness categories.  “Our […]

This new blank check company intends to invest in clean energy businesses. Mary Powell, the retired CEO of Green Mountain Power, will be the chairperson of our board. David Crane, the former CEO of NRG Energy, is our CEO. PIMCO is a co-sponsor of the company. From the prospectus: “Climate change is the foundational issue […]

We are a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative conditions and other diseases. We leverage our proprietary technology platform called TORPEDO (Target ORiented ProtEin Degrader Optimizer) to synthesize a new class of small molecule protein degraders that are […]